GlaucomaNCT07910955
Effects of Balance Training in Individuals With Glaucoma
A study testing Balance Training Program in people with Glaucoma, run by Kanuni Sultan Suleyman Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Glaucoma is a chronic progressive eye disease characterized by visual field loss, which may adversely affect postural control, functional mobility, and increase the risk and fear of falling. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glaucoma
- What is being tested?
- Balance Training Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 5 Aug 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Being over 18 years of age
- Diagnosis of primary open-angle glaucoma
- Glaucoma treatment being stable for the last 3 months (Stable treatment is defined as: no changes to anti-glaucoma medication, no new surgical or laser treatments, and no clinical findings during routine eye examinations necessitating a change in treatment within the last 3 months.)
- Ability to walk independently
- Ability to understand and follow simple verbal commands
- General health status suitable for participating in balance exercises
- Willingness to participate in the study and provide written informed consent
Who cannot join
- Having undergone eye surgery within the last 3 months
- Presence of an eye disease other than glaucoma that could significantly affect balance (e.g., advanced cataract, age-related macular degeneration, proliferative diabetic retinopathy)
- Presence of stroke, Parkinson's disease, multiple sclerosis, or other neurological disorders
- History of vestibular system disorder
- Lower extremity orthopedic condition significantly affecting balance and gait, or lower extremity surgery within the last 6 months
- Presence of cognitive or psychiatric disorders that would hinder adherence to the study
- Presence of severe cardiopulmonary disease that would prevent participation in exercise
- Participation in a regular balance exercise or vestibular rehabilitation program within the last 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Kanuni Sultan Suleyman Education and Research Hospital
Küçükçekmece, Istanbul, 34307
Hatice Zehra FERHATLAR, 05367387869, haticezehraferhatlar@gmail.com
About this study
Official title: Effects of Balance Training on Balance Performance, Fall Risk, and Fear of Falling in Individuals With Glaucoma: A Randomized Controlled Trial
Glaucoma is a chronic progressive eye disease characterized by visual field loss, which may adversely affect postural control, functional mobility, and increase the risk and fear of falling. This randomized controlled trial aims to investigate the effects of balance training on balance performance, fall risk, and fear of falling in individuals with glaucoma. Participants will be randomly assigned to either a balance training group or a control group. The intervention group will participate in a structured balance training program for eight weeks, while the control group will continue their routine medical care. Balance performance, functional mobility/fall risk, and fear of falling will be assessed using the Berg Balance Scale, Timed Up and Go Test, and Falls Efficacy Scale-Internatio
- Conditions
- Glaucoma
- Being tested
- Balance Training Program
- Keywords
- Glaucoma, Balance Training, Postural Balance, Fall Risk, Fear of Falling, Functional Mobility
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Balance Training ProgramBehavioural
Participants allocated to the intervention group will participate in a structured balance training program for 8 weeks, three days per week, with each session lasting approximately 45 minutes. The program will include static and dynamic balance exercises, such as tandem stance, single-leg stance, tandem walking, heel-to-toe walking, directional changes, sit-to-stand exercises, and progressive postural control activities. Exercise difficulty will be progressively increased according to each participant's functional capacity and tolerance. All exercise sessions will be performed under supervision, with appropriate safety precautions to minimize the risk of falls. Participants will continue their routine glaucoma treatment throughout the study.
| Study group | Role | What they receive |
|---|---|---|
| Balance Training Group | Experimental | Participants in this group will receive a structured balance training program for 8 weeks in addition to their routine glaucoma care. The balance training program will include static and dynamic balance exercises, gait-related balance activities, and progressive postural control exercises. Receives: Behavioral: Balance Training Program |
| Control Group | No intervention | Participants in this group will continue their routine glaucoma care and will not receive the balance training program during the 8-week study period. Outcome assessments will be performed at baseline and at the end of 8 weeks using the same assessment procedures as the balance training group. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Balance Performance Assessed by the Berg Balance Scale
Balance performance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 56. Higher scores indicate better balance performance. The change in BBS score from baseline to the end of the 8-week intervention will be evaluated.
Measured: Baseline and 8 weeks
Secondary outcomes (1)
Change in Functional Mobility and Fall Risk Assessed by the Timed Up and Go Test (TUG)
Functional mobility and fall risk will be assessed using the Timed Up and Go Test (TUG). Participants will be instructed to stand up from a standard chair, walk a distance of 3 meters, turn around, walk back to the chair, and sit down. The time required to complete the test will be recorded in seconds. A longer completion time indicates poorer functional mobility and a higher fall risk. The change in TUG time from baseline to the end of the 8-week intervention will be evaluated.
Measured: Baseline and 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2026
- Study start5 Aug 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hatice Zehra FERHATLAR, Kanuni Sultan Suleyman Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07910955
- Sponsor's protocol ID
- GLAU-BAL-2026
- Status last verified
- Oct 2026
- First submitted
- 27 Oct 2026
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Balance Training on Balance Performance, Fall Risk, and Fear of Falling in Individuals With Glaucoma: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07910955
- Acronym / sponsor ID
- GLAU-BAL-2026
- Conditions
- Glaucoma
- Keywords
- Glaucoma, Balance Training, Postural Balance, Fall Risk, Fear of Falling, Functional Mobility
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Kanuni Sultan Suleyman Training and Research HospitalUniversity, hospital or other
- Study start
- 5 Aug 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 2 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Glaucoma is a chronic progressive eye disease characterized by visual field loss, which may adversely affect postural control, functional mobility, and increase the risk and fear of falling. This randomized controlled trial aims to investigate the effects of balance training on balance performance, fall risk, and fear of falling in individuals with glaucoma. Participants will be randomly assigned to either a balance training group or a control group. The intervention group will participate in a structured balance training program for eight weeks, while the control group will continue their routine medical care. Balance performance, functional mobility/fall risk, and fear of falling will be assessed using the Berg Balance Scale, Timed Up and Go Test, and Falls Efficacy Scale-Internatio
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Balance Training Group | Experimental | Behavioral: Balance Training ProgramParticipants in this group will receive a structured balance training program for 8 weeks in addition to their routine glaucoma care. The balance training program will include static and dynamic balance exercises, gait-related balance activities, and progressive postural control exercises. |
| Control Group | No intervention | –Participants in this group will continue their routine glaucoma care and will not receive the balance training program during the 8-week study period. Outcome assessments will be performed at baseline and at the end of 8 weeks using the same assessment procedures as the balance training group. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Being over 18 years of age
- Diagnosis of primary open-angle glaucoma
- Glaucoma treatment being stable for the last 3 months (Stable treatment is defined as: no changes to anti-glaucoma medication, no new surgical or laser treatments, and no clinical findings during routine eye examinations necessitating a change in treatment within the last 3 months.)
- Ability to walk independently
- Ability to understand and follow simple verbal commands
Key exclusion criteria (8 listed)
- Having undergone eye surgery within the last 3 months
- Presence of an eye disease other than glaucoma that could significantly affect balance (e.g., advanced cataract, age-related macular degeneration, proliferative diabetic retinopathy)
- Presence of stroke, Parkinson's disease, multiple sclerosis, or other neurological disorders
- History of vestibular system disorder
- Lower extremity orthopedic condition significantly affecting balance and gait, or lower extremity surgery within the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Balance Training ProgramParticipants allocated to the intervention group will participate in a structured balance training program for 8 weeks, three days per week, with each session lasting approximately 45 minutes. The program will include static and dynamic balance exercises, such as tandem stance, single-leg stance, tandem walking, heel-to-toe walking, directional changes, sit-to-stand exercises, and progressive postural control activities. Exercise difficulty will be progressively increased according to each participant's functional capacity and tolerance. All exercise sessions will be performed under supervision, with appropriate safety precautions to minimize the risk of falls. Participants will continue their routine glaucoma treatment throughout the study. | Behavioural | Balance Training Group |
Primary outcome
Change in Balance Performance Assessed by the Berg Balance Scale
Time frame: Baseline and 8 weeks
Balance performance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 56. Higher scores indicate better balance performance. The change in BBS score from baseline to the end of the 8-week intervention will be evaluated.
1 secondary outcome
Change in Functional Mobility and Fall Risk Assessed by the Timed Up and Go Test (TUG)
Time frame: Baseline and 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
Related trials for Glaucoma
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Not yet recruiting
Glaucoma Drop Aids Part 2
Glaucoma, Intraocular Pressure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Balance Training Program in people with Glaucoma, run by Kanuni Sultan Suleyman Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hatice Zehra FERHATLAR (+905367387869, haticezehraferhatlar@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Balance Performance Assessed by the Berg Balance Scale (time frame: Baseline and 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026; AzTrials last refreshed its copy on 6 Nov 2026.